At Neuronix we have taken a new approach to the treatment of Alzheimer’s Disease (AD). We have designed and developed the world’s first and only medical device that has been shown to enhance the cognitive, behavioral and functional abilities in patients with mild to moderate AD. The treatment is safe, adjunctive to approved Alzheimers’ drugs, clinically proven and provides new hope to Alzheimer’s patients and their caregivers.
Eileen Brannigan - Patient
“I feel like I am back to who I was before…my confidence is back, I don’t feel mentally ill any more”
Robert Dublin - Caregiver
“There has definitely been an improvement. She is the ‘life of the party’ and has had the initiative to go back to painting again.”
Eline Gutelman - Caregiver
“I was able to see improvements and he is now taking piano lessons. The teacher gives him new pieces that he begins to play and remembers. It’s very encouraging.”
Neuronix’s patented technology combines Transcranial Magnetic Stimulation (TMS) with Cognitive Training (CgT). This high safety profile device yields a synergistic effect that improves patients’ cognition and their functional and behavioral capabilities.
Over the past 9 years, Neuronix has conducted clinical studies that have repeatedly validated its results. Patient improvements were evaluated using ADAS-Cog and CGI-C tests. Neuronix’s most recent U.S. multi-center, pivotal clinical study showed a positive and statistically significant difference between the Active Group and Sham Group at 12 weeks follow-up.
Treatment with Neuronix’s neuroAD™ Therapy System is completely non-invasive. Side effects or pain such as headaches or fatigue are mild and rare, and resolve themselves within several hours. Following treatment, you can immediately return to your daily activities.
AN ADJUNCTIVE THERAPY
Treatment with the neuroAD™ Therapy System can be combined with Alzheimer’s drugs and life style changes.